Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells 25,758 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 25,758 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $83.30, for a total transaction of $2,145,641.40. Following the completion of the transaction, the chief operating officer owned 68,052 shares of the company’s stock, valued at $5,668,731.60. This trade represents a 27.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kymera Therapeutics Stock Down 3.6%

Shares of KYMR stock traded down $3.06 during mid-day trading on Wednesday, hitting $81.52. 688,882 shares of the stock traded hands, compared to its average volume of 797,469. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00. The company’s 50-day simple moving average is $79.02 and its 200-day simple moving average is $67.73.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The firm had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.88) EPS. Equities analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP increased its stake in Kymera Therapeutics by 30.2% in the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC increased its stake in shares of Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after purchasing an additional 1,061,957 shares during the last quarter. Finally, BVF Inc. IL increased its position in Kymera Therapeutics by 6.6% in the 2nd quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after purchasing an additional 340,909 shares during the last quarter.

Analyst Ratings Changes

KYMR has been the subject of a number of recent research reports. Barclays increased their price objective on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research report on Tuesday, January 27th. UBS Group boosted their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Jefferies Financial Group increased their price target on Kymera Therapeutics from $73.00 to $122.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Mizuho lifted their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Finally, Stephens boosted their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.